Analysis of financing of drug programs in allergology in 2020–2024

Introduction
This article presents a detailed analysis of financing of drug programs in allergology in Poland in the years 2020–2024. Polish allergology faces many significant challenges, including increased incidence of allergic diseases and a limited number of allergy outpatient clinics. The article emphasizes that access to modern therapies and biological drugs that can significantly improve the quality of life of patients.

Aim
The aim of the study is to analyse the implementation of allergy services, taking into account the number of drug programs, the value of contracts with the National Health Fund for conducting drug programs and the number of patients in drug programs.

Material and methods
The material and methods section includes publicly available data provided by the National Health Fund (NFZ), the Ministry of Health and the Central Statistical Office (GUS).

Conclusions
The conclusions from the analysis indicate the dynamic development of drug programs in allergology, both in terms of the number of programs, the number of patients and the value of financing. The introduction of new programs, such as B.124 concerning the treatment of atopic dermatitis, shows that the healthcare system is trying to respond to the needs of patients and the appeals of the allergology community. At the same time, data published by the National Health Fund indicate growing queues of patients waiting for services, which shows that the waiting time for a visit in both outpatient and inpatient conditions is getting longer.